In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
Poster 5 Pre-assessment

Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

MD/DO

Nurse

Other (please specify)

Question Title

* 2. What is your specialty?

Oncology

Hematology

Pediatrics

Primary Care/Family Medicine

Other (please specify)

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 4. Which of the following is best describes outcomes associated with addition of 1 cycle of nelarabine in adults with ALL based on the UKALL14 study?

Improves event-free survival

Increases treatment-related mortality

Not beneficial

Improves overall survival

Question Title

* 5. An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCRg deletion (ABD) were associated with which of the following outcomes?

Improved response to nelarabine

Improved rate of MRD-negativity after phase 1

Improved rate of MRD-negativity after phase 2

Increased risk of relapse

Question Title

* 6. Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of first-line therapy on the GRAAPH 2014 protocol for Philadelphia chromosome positive acute lymphoblastic leukemia is associated with:

Decreased overall survival in patients who did not receive a transplant

No change in the incidence of relapse

Improvement in complete response rate

Improvement achievement of MRD negativity at cycle 4

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 5 Pre-assessment***

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your specialty?

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Question Title

* 4. Which of the following is best describes outcomes associated with addition of 1 cycle of nelarabine in adults with ALL based on the UKALL14 study?

Question Title

* 5. An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCRg deletion (ABD) were associated with which of the following outcomes?

Question Title

* 6. Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of first-line therapy on the GRAAPH 2014 protocol for Philadelphia chromosome positive acute lymphoblastic leukemia is associated with:

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
Poster 5 Pre-assessment